2-pyridin-2-yl-pyrazolo[1,5-a]pyridine-3-carboxylic acid | 676343-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 2-pyridin-2-yl-pyrazolo[1,5-a]pyridine-3-carboxylic acid
• 英文别名: 2-Pyridin-2-ylpyrazolo[1,5-a]pyridine-3-carboxylic acid
• CAS: 676343-24-1
• 化学式: C₁₃H₉N₃O₂
• 分子量: 239.233
• InChiKey: FXTKRFYBFZBKMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-5-氯-2-(5-甲基-[1,4]二氮杂环庚烷-1-基)-苯并噁唑盐酸盐 、 2-pyridin-2-yl-pyrazolo[1,5-a]pyridine-3-carboxylic acid 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以100 %的产率得到
  参考文献：
  名称：

  SUBSTITUTED PYRAZOLES AND IMIDAZOLES AS OREXIN RECEPTOR ANTAGONISTS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS

  摘要：

  The disclosure relates to substituted Imidazole and Pyrazole ring system derivatives of compounds that are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved or implicated. This disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  公开号：

  WO2024044351A2
• 作为产物：
  描述：

  2-乙炔基吡啶 在 正丁基锂 、 水 、 potassium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.5h， 生成 2-pyridin-2-yl-pyrazolo[1,5-a]pyridine-3-carboxylic acid
  参考文献：
  名称：

  SUBSTITUTED PYRAZOLES AND IMIDAZOLES AS OREXIN RECEPTOR ANTAGONISTS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS

  摘要：

  The disclosure relates to substituted Imidazole and Pyrazole ring system derivatives of compounds that are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved or implicated. This disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  公开号：

  WO2024044351A2

文献信息

• PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：ELI LILLY AND COMPANY

  公开号：EP1543001B1

  公开（公告）日：2007-08-15